List of Excipients in Branded Drug NIACOR

Generic Drugs Containing NIACOR

Company	Ingredient	NDC	Excipient
Avondale Pharmaceuticals LLC	niacin	71740-001	CELLULOSE, MICROCRYSTALLINE
Avondale Pharmaceuticals LLC	niacin	71740-001	CROSCARMELLOSE SODIUM
Avondale Pharmaceuticals LLC	niacin	71740-001	HYDROGENATED SOYBEAN OIL
Avondale Pharmaceuticals LLC	niacin	71740-001	MAGNESIUM STEARATE
Avondale Pharmaceuticals LLC	niacin	71740-201	CELLULOSE, MICROCRYSTALLINE
Avondale Pharmaceuticals LLC	niacin	71740-201	CROSCARMELLOSE SODIUM
Avondale Pharmaceuticals LLC	niacin	71740-201	HYDROGENATED SOYBEAN OIL

What are the Most Frequently-Used Excipients in NIACOR?

# Of NDCs	Excipient
2	CELLULOSE, MICROCRYSTALLINE
2	CROSCARMELLOSE SODIUM
2	HYDROGENATED SOYBEAN OIL
2	MAGNESIUM STEARATE

NIACOR Excipient Strategy and Commercial Opportunities: Formulation, Generic Entry, and Market Outlook

Last updated: August 8, 2026

NIACOR is an immediate-release prescription niacin product used to manage dyslipidemia. Its commercial opportunity is primarily formulation-led rather than patent-led. The strongest opportunities are low-cost generic supply, excipient-controlled tablet performance, differentiated tolerability, contract manufacturing, and combination packaging. The product has limited exclusivity value because niacin is an established active ingredient and the principal commercial barriers are regulatory execution, supply reliability, physician acceptance, and competition from statins and newer lipid-lowering therapies.

What is NIACOR and which formulation does it use?

NIACOR is an oral niacin tablet. Niacin, also known as nicotinic acid or vitamin B3, reduces triglycerides and LDL cholesterol while increasing HDL cholesterol. The product is distinct from extended-release niacin products such as NIASPAN because NIACOR uses an immediate-release tablet presentation.

The distinction matters for excipient strategy. Immediate-release niacin does not require a sustained-release matrix, osmotic system, multiparticulate coating, or complex release-controlling polymer. Its formulation priorities are:

• Rapid and consistent disintegration
• Reliable dissolution across strengths
• Tablet hardness sufficient for packaging and transport
• Low friability
• Dose uniformity
• Moisture and oxidation control
• Acceptable color, appearance, and swallowability
• Manufacturing cost control

FDA labeling identifies inactive ingredients for the marketed product, but the excipient profile can vary between NIACOR-manufactured products, authorized generics, and ANDA products. A commercial developer should treat the current FDA labeling and approved product-specific chemistry, manufacturing, and controls documentation as controlling sources for composition and equivalence analysis. [1]

What excipients are strategically important in NIACOR tablets?

The highest-value excipient decisions concern tablet compression, disintegration, coating or film protection, and patient tolerability.

Fillers and compression aids

Microcrystalline cellulose, lactose, mannitol, dicalcium phosphate, and pregelatinized starch are potential diluents for niacin tablets. The selection affects:

• Tablet weight
• Compression force
• Friability
• Disintegration time
• Moisture sensitivity
• Cost per dose
• Compatibility with direct compression or granulation

Microcrystalline cellulose is commercially attractive because it supports direct compression and provides good compactibility at relatively low concentrations. Lactose can lower cost but may create compatibility or moisture-management issues depending on the formulation and manufacturing process. Mannitol can improve mouthfeel but usually carries a higher cost and may not provide the same compression profile as microcrystalline cellulose.

For a generic NIACOR program, the preferred starting strategy is a simple direct-compression formulation unless the reference product requires a granulation process to achieve dissolution or content uniformity.

Disintegrants

Crospovidone, croscarmellose sodium, and sodium starch glycolate are the main disintegrant candidates. Their performance depends on:

• Use level
• Particle size
• Compression force
• Tablet porosity
• Lubricant concentration
• Granulation history

Crospovidone can provide rapid liquid wicking and robust disintegration. Croscarmellose sodium can offer strong swelling and is widely used in immediate-release tablets. Sodium starch glycolate can deliver rapid swelling but may be more sensitive to compression and formulation balance.

The commercial objective is not simply the shortest disintegration time. Excessive disintegrant levels can weaken tablets, increase friability, or complicate scale-up. The target should be a dissolution profile that matches the reference product while preserving tablet integrity.

Binders

Povidone, pregelatinized starch, hydroxypropyl cellulose, and low-substituted hydroxypropyl cellulose may be used to improve granule or tablet strength. Binders become more important if niacin is processed by wet granulation.

A high binder concentration can delay disintegration and dissolution. A low binder concentration can produce capping, lamination, and excessive friability. For NIACOR, the formulation should use the minimum binder level that supports commercial compression and packaging.

Lubricants and glidants

Magnesium stearate is a common lubricant for niacin tablets. Colloidal silicon dioxide, talc, and similar materials can improve powder flow and reduce manufacturing variability.

Over-lubrication with magnesium stearate can create hydrophobic particle surfaces, slow wetting, and reduce dissolution. This is a central development risk in immediate-release tablets. Lubricant blending time, lubricant concentration, and shear exposure should be treated as critical process parameters.

A commercial formulation should establish a defined design space for:

• Magnesium stearate concentration
• Lubrication time
• Blender speed
• Blend uniformity
• Compression force
• Tablet porosity

Film-forming and protective excipients

A film coat can improve appearance, reduce dusting, protect against moisture, and improve swallowability. Hypromellose, polyvinyl alcohol, polyethylene glycol, titanium dioxide, talc, and approved colorants are common coating components.

A film coat is commercially useful if it improves product handling without materially delaying dissolution. The coat should remain thin enough to preserve immediate release. Color differentiation between strengths can reduce dispensing errors and support pharmacy handling.

The main strategic choice is whether to retain a plain tablet or use a film-coated presentation. A plain tablet minimizes cost and process complexity. A film-coated tablet may support stronger packaging differentiation and better patient acceptance, particularly for higher strengths.

What formulation problems are associated with niacin?

Niacin is associated with flushing, warmth, itching, and gastrointestinal discomfort. These effects are pharmacologic and cannot be eliminated through excipients alone. Excipient selection can improve product usability, but it cannot convert an immediate-release niacin tablet into a low-flush product without changing the release profile or clinical exposure.

The formulation risks include:

1. Excessively rapid dissolution, which may contribute to a sharp systemic exposure profile.
2. Delayed dissolution caused by over-lubrication or excessive coating.
3. Tablet odor or taste concerns during swallowing or oral handling.
4. Moisture-related changes in hardness, disintegration, or assay.
5. Colorant intolerance or excipient sensitivity in a small patient population.

A company seeking a differentiated niacin product should avoid unsupported claims that an excipient change reduces flushing. Such a claim could create clinical, labeling, and regulatory requirements beyond a conventional generic pathway.

What patents protect NIACOR and when does NIACOR lose exclusivity?

NIACOR’s principal active ingredient, niacin, is an old and widely used compound. The commercial value of the product is therefore not based on composition-of-matter protection. Any relevant protection would more likely involve:

• A specific formulation
• A release profile
• A manufacturing process
• A dosage regimen
• A combination product
• A proprietary coating or delivery system

The FDA Orange Book is the primary source for identifying patents and regulatory exclusivity associated with an approved listed drug. A current review should cover the NIACOR reference product’s NDA listing, patent certification data, therapeutic-equivalence evaluations, and any listed patents. [2]

For a conventional immediate-release niacin tablet, the expected barrier to entry is low if no active formulation or method-of-use patents are listed. Patent risk is more relevant for a redesigned low-flush formulation, controlled-release formulation, or niacin combination product than for a standard immediate-release tablet.

What is the Orange Book status of NIACOR?

The Orange Book determines whether an approved reference product has listed patents or exclusivity that could affect ANDA approval. NIACOR should be assessed through:

• The current Electronic Orange Book listing
• FDA Drugs@FDA records
• Current labeling
• Discontinued-drug status, if applicable
• Any listed patent delistings or changes
• Therapeutic-equivalence codes for competing niacin products

A product’s commercial availability and an NDA’s regulatory status are not always identical. A brand may be discontinued commercially while an approved application remains in FDA records. That distinction matters for reference-product selection, ANDA strategy, and potential 505(b)(2) planning.

Are Paragraph IV challenges and generic entry risks significant for NIACOR?

For an immediate-release niacin tablet, Paragraph IV risk is generally lower than for a patented modified-release product. The relevant generic-entry pathways are:

Entry pathway	Commercial relevance
ANDA	Primary route for a therapeutically equivalent immediate-release tablet
505(b)(2) application	Relevant for a materially differentiated formulation, dosing regimen, or clinical profile
Authorized generic	Possible where a brand owner or licensee supplies an equivalent product
OTC pathway	Requires separate regulatory and labeling analysis; prescription use does not automatically convert to OTC status

A Paragraph IV certification would matter only if an Orange Book-listed patent covered the reference product. If the product has no active listed patent, an ANDA applicant may face a conventional approval pathway rather than patent litigation.

Generic entry risks remain commercially meaningful because of:

• Low manufacturing complexity
• Multiple potential niacin suppliers
• Limited technological differentiation
• Pharmacy substitution
• Price pressure
• Competition from generic statins
• Reduced use of niacin in contemporary lipid management

The strongest generic strategy is usually cost leadership supported by reliable supply, clean dissolution data, and limited product complexity.

What excipient opportunities can differentiate a NIACOR competitor?

Low-cost standard tablet

This is the most direct opportunity. The formulation would use widely available excipients, direct compression where feasible, conventional packaging, and limited strength-specific complexity.

Commercial advantages include:

• Low development cost
• Shorter scale-up cycle
• Broad supplier availability
• Simplified quality control
• Lower unit cost

This strategy is suitable for institutional, wholesaler, and value-oriented pharmacy channels.

Improved swallowability

A film-coated tablet with controlled tablet dimensions, smoother surface characteristics, and strength-specific color coding could improve patient handling. The opportunity is modest but practical because it does not require a new clinical claim.

Excipient-reduced formulation

A formulation with fewer excipients may appeal to patients and institutions seeking lower allergen or intolerance burden. The principal challenge is preserving manufacturability and dissolution while removing colorants, lactose, or other nonessential components.

The commercial message should remain factual. "Contains fewer inactive ingredients" is supportable if documented. Claims involving improved tolerability require appropriate evidence.

Moisture-robust formulation and packaging

A moisture-resistant formulation could reduce assay and dissolution drift during storage. Blister packaging, high-barrier bottles, desiccants, and induction seals may be more commercially valuable than a novel excipient.

Packaging opportunities include:

• Unit-dose blister packs for institutional use
• Calendar packaging to support adherence
• High-barrier bottles for retail distribution
• Strength-specific color systems
• Tamper-evident packaging
• Smaller fills for specialty and hospital channels

Combination-product positioning

Niacin could be packaged with other lipid-lowering therapies, but a fixed-dose combination would require substantial regulatory and clinical work. Combination packaging is simpler than a fixed-dose combination and may provide a lower-risk commercial test.

How does NIACOR compare with extended-release niacin products?

Attribute	NIACOR immediate-release niacin	Extended-release niacin
Release design	Immediate release	Modified release
Excipient complexity	Low to moderate	Moderate to high
Main formulation objective	Rapid dissolution and dose uniformity	Controlled exposure and release
Patent risk	Typically lower for legacy immediate-release products	Potentially higher for formulation-specific products
Flushing profile	Immediate-release niacin can cause flushing	Release design may alter exposure and tolerability
Generic development	Generally more straightforward	More demanding bioequivalence and dissolution program
Commercial differentiation	Cost, supply, packaging, usability	Release technology, dosing, tolerability, clinical positioning

A developer should not assume that an excipient strategy for NIACOR can be transferred to an extended-release niacin product. Modified-release products require a separate risk assessment covering in vitro release, food effects, alcohol sensitivity where relevant, pharmacokinetics, and clinical equivalence.

What regulatory issues affect NIACOR excipient changes?

For an ANDA, the formulation must meet the applicable requirements for pharmaceutical equivalence and bioequivalence. The product generally must match the reference drug in active ingredient, dosage form, route, strength, and relevant performance characteristics, subject to FDA requirements. [3]

A post-approval excipient change can require:

• Comparative dissolution
• Stability data
• Updated manufacturing controls
• CMC supplements
• Labeling review
• Bioequivalence assessment, depending on the change
• Assessment under FDA post-approval change guidance

FDA’s SUPAC framework provides a basis for evaluating certain formulation and process changes in immediate-release solid oral dosage forms. [4] The change category depends on the type and scale of modification, manufacturing impact, and demonstrated product performance.

For NIACOR, high-risk changes include:

• Changing the release-controlling mechanism
• Replacing a major diluent or binder
• Altering lubricant concentration materially
• Changing granulation from wet to dry or direct compression
• Introducing a new coating system
• Changing tablet dimensions or score configuration
• Moving to a different API particle-size distribution

What manufacturing and intellectual-property barriers affect NIACOR?

Manufacturing barriers are operational rather than technologically difficult. The critical controls are:

• API particle-size distribution
• Blend uniformity
• Lubrication endpoint
• Compression force
• Tablet weight and hardness
• Disintegration
• Dissolution
• Moisture exposure
• Packaging seal integrity

Niacin API supply is likely to be less differentiated than specialized lipid-lowering APIs. Supplier qualification, impurity control, geographic redundancy, and change-control discipline therefore have greater commercial value than proprietary excipient technology.

The most defensible IP opportunities would involve a demonstrably differentiated formulation, manufacturing process, delivery system, or combination product. A routine excipient substitution is unlikely to produce durable patent value unless it creates an unexpected technical effect supported by comparative data.

Which companies are challenging NIACOR commercially?

The competitive set includes:

• Generic niacin tablet manufacturers
• Suppliers of extended-release niacin
• Generic statin manufacturers
• Combination lipid-lowering products
• PCSK9 inhibitors
• ATP-citrate lyase inhibitors
• Fibrates and omega-3 products
• Pharmacy and institutional suppliers

The most important competitive pressure does not come from another immediate-release niacin tablet. It comes from clinical substitution toward therapies with stronger contemporary guideline positioning and more predictable cardiovascular-outcome evidence.

A NIACOR competitor therefore needs a defined channel strategy. Retail pharmacy competition favors low acquisition cost and reliable fill rates. Institutional buyers favor supply continuity, unit-dose packaging, and standardized strengths. Specialty channels may value adherence packaging and simplified procurement.

What commercial opportunities exist for NIACOR excipient developers?

The most credible opportunities are:

1. A therapeutically equivalent, low-cost immediate-release generic.
2. A manufacturing platform that improves dissolution consistency.
3. A film-coated product with better handling and strength differentiation.
4. A moisture-robust presentation for institutional and mail-order distribution.
5. A small-excipient or colorant-free variant, subject to regulatory feasibility.
6. Co-packaging with other lipid-lowering medicines.
7. Contract development and manufacturing services for niacin tablets.
8. Regional supply partnerships in markets with limited access to lipid medicines.
9. Private-label supply for wholesalers and health systems.
10. A 505(b)(2) program only where a clinically meaningful formulation distinction exists.

Revenue exposure is difficult to quantify from public information because NIACOR-specific sales may not be separately reported. The economic profile is more likely to resemble a mature generic or legacy branded product than a protected specialty medicine. Margin depends on procurement contracts, API cost, manufacturing scale, wholesaler discounts, and supply reliability.

Key Takeaways

• NIACOR is an immediate-release niacin tablet, so excipient complexity is lower than for extended-release niacin.
• The principal formulation targets are dissolution, disintegration, compression performance, moisture control, and tablet usability.
• Excipients cannot support unsupported claims that the product reduces niacin flushing.
• The principal commercial opportunity is a reliable, low-cost generic or differentiated package rather than a high-value patent platform.
• Orange Book review is necessary to confirm current listed patents, exclusivity, and reference-product status.
• Paragraph IV risk is likely to be limited for a conventional immediate-release product unless an active formulation or method patent is listed.
• The strongest IP opportunity is a validated formulation, manufacturing process, or delivery system with measurable technical advantages.
• Competitive risk comes mainly from alternative lipid-lowering therapies, especially statins and newer agents, rather than from other niacin tablets.

FAQs

Can NIACOR be reformulated with different excipients?

Yes, but the regulatory impact depends on the change. A generic product must demonstrate pharmaceutical equivalence and acceptable performance against the reference product. Material changes may require additional dissolution, stability, manufacturing, or bioequivalence work.

Is a niacin excipient patent commercially valuable?

Only if the excipient system produces a defensible and unexpected technical effect, such as a reproducible release, stability, or manufacturing advantage. Routine substitution of common fillers, binders, or lubricants usually provides limited patent durability.

Does film coating change NIACOR’s regulatory pathway?

A film coat does not automatically create a new regulatory pathway. The product must still meet applicable equivalence, dissolution, stability, and manufacturing requirements. A coating that changes release or exposure can materially increase regulatory complexity.

Is a low-flush NIACOR product possible?

A meaningful change in flushing may require a modified-release profile, dosing change, or clinical intervention rather than a simple excipient substitution. A developer should not make a low-flush claim without clinical and regulatory support.

Could NIACOR be converted from prescription to over-the-counter status?

Potentially, but prescription status does not convert automatically. An OTC program would require a separate assessment of labeling, consumer comprehension, dosing, safety, misuse risk, and FDA regulatory requirements. The commercial case would also depend on whether the OTC product competes with inexpensive dietary niacin supplements.

References

1. U.S. Food and Drug Administration. (n.d.). NIACOR (niacin) tablet prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

3. U.S. Food and Drug Administration. (2003). Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug products: General considerations.

4. U.S. Food and Drug Administration. (1995). SUPAC-IR: Immediate-release solid oral dosage forms: Scale-up and post-approval changes.